🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Really great first "IBD Drive" podcast Gastroenterology Learning Network by Raymond Cross & Millie Long -- discussing SERENE-UC & STARDUST trials (and 'take-homes') in IBD gastroenterologylearningnetwork.com/podcasts/ibd-d…

Nice Table 1 highlights similarities (and few key differences) btw American Gastroenterological Association (AGA) ACG Y-ECCO Crohn’s Disease Guidelines gastrojournal.org/article/S0016-…

Calprotectin’s mechanistic functions — beyond the clinician’s diagnostic aid and IBD monitoring biomarker… Gut Journal gut.bmj.com/content/early/…

Interesting re potential adjunct use of certain oral antibiotic classes to reduce anti-drug antibody formation in IBD Gut Journal gut.bmj.com/content/early/…

CD but not UC associated w increased dz incidence from ultra-processed foods? #diet #IBD CGH cghjournal.org/article/S1542-…

How IBD meds potentially alter vaccine response Nice review paper roypounder.apt onlinelibrary.wiley.com/doi/10.1111/ap…

Cost-effectiveness of treat-to-target of biomarker-based (symptom+calpro) vs endoscopy-based (SES-CD) in Crohn's disease -- hybrid model wins... AJG - The American Journal of Gastroenterology journals.lww.com/ajg/Abstract/2…

Two goodies on (racial/ethnic) diversity and representation in #IBDTrials Gastroenterology -- and why it matters sciencedirect.com/science/articl… pubmed.ncbi.nlm.nih.gov/34562464/

Review: Leveraging diet to engineer the gut microbiome Nature Reviews Gastroenterology & Hepatology -- needing more evidence on *HOW* specific diets alter human (less rodent) gut immunity nature.com/articles/s4157…

Crohn’s Disease Trials & Placebo Rates: Higher PBO when: 1) increased trial duration, 2) increased follow-up visits, 3) higher % of colonic disease location Lower PBO when: 1) pts had prior biologics, 2) longer dz duration, 3) increased dz severity pubmed.ncbi.nlm.nih.gov/34758084/

Unmet Medical Need in #UlcerativeColitis: Israeli Epi study showing comparable colectomy rates pre- vs post-biologics era by iris dotan & Dan Turner et al. #EfficacyCeiling academic.oup.com/ecco-jcc/advan…

Humoral immunity response post-COVID19 vaccination among IBD patients on anti-TNF-α ± Immunomodulators (group 2) vs less-systemically active immunosuppressives. Nice Research Letter Dana Lukin MD, PhD CGH ncbi.nlm.nih.gov/pmc/articles/P…

"Developing a cadre of clinician trialists in gastroenterology and hepatology" by @nuru_noor1 - Indeed! Nature Reviews Gastroenterology & Hepatology nature.com/articles/s4157…

.IOIBD Clinical development recs for ulcerative proctitis pubmed.ncbi.nlm.nih.gov/35189386/ #clinicaltrials #endpoints #IBD CGH

Developing therapies are limited to moderate-to-severe IBD. Few development considerations for mild-to-moderate Crohn's disease pubmed.ncbi.nlm.nih.gov/35240140/

Thinking about the cost-effectiveness of virtual vs in-person meetings and scientific collaborations nature nature.com/articles/d4158…

Akkermansia muciniphila: such a cool bug… #GutImmunity #ImmuneRegulation Nature Reviews Gastroenterology & Hepatology nature.com/articles/s4157…

Many future GI applications... Engineered #microbiome therapy to prevent gut dysbiosis... nature.com/articles/s4155…

Thinking about *B-cell* dysfunction in #IBD (esp #UlcerativeColitis) #celiac: cross-talk w T-cells, resulting gut dysbiosis #microbiota Nice title: "Tango of B cells with T cells in the making of secretory antibodies to gut bacteria" Nature Reviews Gastroenterology & Hepatology nature.com/articles/s4157…

Persistent question for the #IBD community reading this publication... #ClinicalTrials academic.oup.com/ecco-jcc/advan…